NCT04523818View on ClinicalTrials.gov

Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Clinical Stage I Gastric Cancer AJCC v8Clinical Stage IIA Gastric Cancer AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8Gastric AdenocarcinomaPathologic Stage IB Gastric Cancer AJCC v8Pathologic Stage II Gastric Cancer AJCC v8Pathologic Stage IIA Gastric Cancer AJCC v8Pathologic Stage IIB Gastric Cancer AJCC v8Pathologic Stage III Gastric Cancer AJCC v8Pathologic Stage IIIA Gastric Cancer AJCC v8Pathologic Stage IIIB Gastric Cancer AJCC v8Pathologic Stage IIIC Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8
Interventions
DRUG

Capecitabine

Given PO

DRUG

Fluorouracil

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

PROCEDURE

Therapeutic Surgical Procedure

Undergo standard of care surgery

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT04523818 - Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma | Biotech Hunter | Biotech Hunter